Survival of breast cancer patients in rural Ethiopia

Breast Cancer Research and Treatment
Pia Eber-SchulzEva Johanna Kantelhardt

Abstract

To describe the histopathological characteristics and survival of female breast cancer (BC) patients in a rural setting with limited access to adjuvant treatment. A prospective study of 107 histologically confirmed BC patients treated with surgery from 2010 to 2016 from rural parts of western Ethiopia. Referral pathology was performed, and active follow-up was conducted. Adjusted cox regression analysis (hazard ratio [HR]) was performed. The median age at diagnosis was 45 (16-83) years; 57% of the patients presented with cT3/4 tumors, 71% with clinically positive lymph nodes, 21% with HER2-overexpression (Dako3+) and 68% with grade 3 tumors. Estrogen and/or progesterone receptor expressions were present in 66% and triple-negative disease in 25%. The estimated 1- and 2-year overall survival probability rates were 78 and 53%, respectively. The 2-year survival for patients with clinically positive lymph nodes was 44% compared to 73% for patients with lymph node-negative disease (HR 2.44; 95% confidence interval [95% CI] 1.19-5.02). The corresponding 2-year survival for patients with cT4 tumors was 25% versus 68% for patients with cT1-2 tumors (cT1-3 vs. cT4 HR 3.86; 95% CI 1.82-13.63). The 2-year survival for patients with hormone...Continue Reading

References

Aug 1, 1996·Controlled Clinical Trials·M Schemper, T L Smith
May 8, 2000·Journal of Surgical Oncology·P A JohnstoneR H Riffenburgh
Mar 29, 2001·International Journal of Health Services : Planning, Administration, Evaluation·S Iliffe
Jun 8, 2002·Applied Immunohistochemistry & Molecular Morphology : AIMM·Daniel A Arber
Jun 26, 2008·British Journal of Cancer·A GakwayaD Kanyike
Aug 17, 2011·Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen·Regine WoltersRolf Kreienberg
Aug 25, 2011·Journal of the National Cancer Institute·Rengaswamy SankaranarayananBeela Sara Mathew
Feb 9, 2012·International Journal of Breast Cancer·Timothy D DyeAnne Reeler
Apr 18, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gunter von MinckwitzSibylle Loibl
Feb 5, 2013·The Lancet Oncology·Eugenio Panieri
Jan 1, 2014·International Journal of Cancer. Journal International Du Cancer·E J KantelhardtS Bogale
Apr 5, 2014·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·D Maxwell ParkinAhmedin Jemal
Jul 12, 2014·The Breast : Official Journal of the European Society of Mastology·Shahin SayedMansoor Saleh
Nov 20, 2014·International Journal of Cancer. Journal International Du Cancer·Twalib NgomaJames F Holland
Dec 1, 2014·BMC Cancer·Eva Johanna KantelhardtBekuretsion Yonas
May 6, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A S CoatesUNKNOWN Panel Members
Nov 20, 2016·The Lancet Global Health·Elima Jedy-AgbaIsabel Dos-Santos-Silva
Feb 8, 2018·Cancer Epidemiology·Genebo TimotewosEva Johanna Kantelhardt

❮ Previous
Next ❯

Citations

Aug 29, 2019·BMC Cancer·Abigiya WondimagegnehuSolomon Teferra
Sep 20, 2019·PloS One·Jana FeuchtnerEva Johanna Kantelhardt
May 10, 2020·American Journal of Epidemiology·Milena FoersterValerie McCormack
Sep 20, 2020·Breast Cancer Research and Treatment·Alem GebremariamAhmedin Jemal
Apr 15, 2019·The Breast Journal·Agnieszka KołacińskaAndrzej Śliwczyński
Oct 4, 2020·BMC Health Services Research·Hannes-Viktor ZiegenhornEva Johanna Kantelhardt
Jun 19, 2021·Annals of Biomedical Engineering·Alyssa D SchwartzCourtney C Babbitt
Nov 2, 2021·Breast Care·Christian Felix ReiboldEva Johanna Kantelhardt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.